Development
ADMA Biologics, Inc.
ADMA
$18.96
-$0.95-4.77%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 258.22M | 234.29M | 208.11M | 181.89M | 154.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 258.22M | 234.29M | 208.11M | 181.89M | 154.08M |
| Cost of Revenue | 167.17M | 160.16M | 148.97M | 133.77M | 118.81M |
| Gross Profit | 91.04M | 74.13M | 59.14M | 48.12M | 35.26M |
| SG&A Expenses | 61.89M | 64.65M | 67.91M | 68.92M | 70.30M |
| Depreciation & Amortization | 723.90K | 714.90K | 714.90K | 714.90K | 714.90K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 233.08M | 229.45M | 221.97M | 207.25M | 193.45M |
| Operating Income | 25.13M | 4.84M | -13.86M | -25.36M | -39.37M |
| Income Before Tax | -28.24M | -22.83M | -40.29M | -47.68M | -65.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.24 | -22.83 | -40.29 | -47.68 | -65.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.24M | -22.83M | -40.29M | -47.68M | -65.90M |
| EBIT | 25.13M | 4.84M | -13.86M | -25.36M | -39.37M |
| EBITDA | 33.46M | 13.00M | -5.93M | -17.81M | -32.25M |
| EPS Basic | -0.13 | -0.11 | -0.20 | -0.24 | -0.33 |
| Normalized Basic EPS | 0.00 | -0.06 | -0.11 | -0.15 | -0.19 |
| EPS Diluted | -0.13 | -0.11 | -0.20 | -0.24 | -0.34 |
| Normalized Diluted EPS | 0.00 | -0.06 | -0.11 | -0.15 | -0.19 |
| Average Basic Shares Outstanding | 895.85M | 872.71M | 843.82M | 817.49M | 791.44M |
| Average Diluted Shares Outstanding | 904.33M | 881.20M | 843.82M | 817.49M | 791.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |